Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint Journal Article


Authors: Hellmann, M. D.; Chaft, J. E.; William, W. N.; Rusch, V.; Pisters, K. M. W.; Kalhor, N.; Pataer, A.; Travis, W. D.; Swisher, S. G.; Kris, M. G.
Article Title: Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint
Abstract: Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. A surrogate for survival, such as pathological response to neoadjuvant chemotherapy, has the potential to improve the efficiency of trials and expedite advances. 10% or less residual viable tumour after neoadjuvant chemotherapy, termed here major pathological response, meets criteria for a surrogate; major pathological response strongly associates with improved survival, is reflective of treatment effect, and captures the magnitude of the treatment benefit on survival. We support the incorporation of major pathological response as a surrogate endpoint for survival in future neoadjuvant trials of resectable lung cancers. Additional prospective studies are needed to confirm the validity and reproducibility of major pathological response within individual histological and molecular subgroups and with new drugs. © 2014 Elsevier Ltd.
Journal Title: Lancet Oncology
Volume: 15
Issue: 1
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2014-01-01
Start Page: e42
End Page: e50
Language: English
DOI: 10.1016/s1470-2045(13)70334-6
PROVIDER: scopus
PUBMED: 24384493
PMCID: PMC4734624
DOI/URL:
Notes: Export Date: 3 February 2014 -- CODEN: LOANB -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Valerie W Rusch
    735 Rusch
  2. Jamie Erin Chaft
    163 Chaft
  3. William D Travis
    606 Travis
  4. Mark Kris
    716 Kris
  5. Matthew David Hellmann
    257 Hellmann